Drugs / HB0028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06223308 | Sep 2022 → May 2024 | cervical cancer | Shanghai Huaota Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06223308 ↗ |
| Modality | Protein / enzyme biologic | “Anti-PD-L1 and TGF-β bifunctional fusion protein” NCT06223308 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT06223308 ↗ |